A new Phase 2 clinical trial of tesetaxel in men with castrate resistant advanced prostate cancer will be conducted through the Prostate Cancer Clinical Trials Consortium (PCCTC). Tesetaxel, an oral taxane which is in clinical development, will be evaluated for its use as both first- and second-line chemotherapy. […]
Researchers at the Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy performed a randomized phase II study which compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the standard of care D/prednisone (P) in men with advanced castrate-resistant prostate cancer (CRPC). […]
An article appearing today the Urology Times E-News rang a warning bell about the use of the angiogenesis inhibitor bevacizumab (Avastin). The article warned that men with advanced prostate cancer may be at an increased risk of treatment-related death when bevacizumab is used in combination with other therapies. Senior author Shenhong Wu, MD, PhD, and [...]
We have been having a lot of conversations on the advanced prostate cancer on-line group this last month about chemotherapy. Three of our advanced prostate cancer warriors have been openly sharing their experiences as they start docetaxel (taxotere or chemotherapy). Join the group at: Join the advanced prostate cancer on-line support group. It is important [...]
Can IxMP Be Used as a Second or Third-Line Chemotherapy for Metastatic Castrate Resistant Prostate Cancer? There was a report recently released about a Phase 2 study from the Department of Defense funded Prostate Cancer Clinical Trials Consortium that suggests that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of [...]